JP2008540558A - ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 - Google Patents

ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 Download PDF

Info

Publication number
JP2008540558A
JP2008540558A JP2008511345A JP2008511345A JP2008540558A JP 2008540558 A JP2008540558 A JP 2008540558A JP 2008511345 A JP2008511345 A JP 2008511345A JP 2008511345 A JP2008511345 A JP 2008511345A JP 2008540558 A JP2008540558 A JP 2008540558A
Authority
JP
Japan
Prior art keywords
micelle
group
micelles
polymer
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540558A5 (https=
Inventor
バリ プレンドラン，
ニレン マーシー，
ロバート エイチ． ピアース，
マイケル ジェイ． ヘファーナン，
チファ ハオ，
マーシン クウィッサ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Publication of JP2008540558A publication Critical patent/JP2008540558A/ja
Publication of JP2008540558A5 publication Critical patent/JP2008540558A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G4/00—Condensation polymers of aldehydes or ketones with polyalcohols; Addition polymers of heterocyclic oxygen compounds containing in the ring at least once the grouping —O—C—O—
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L59/00—Compositions of polyacetals; Compositions of derivatives of polyacetals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
JP2008511345A 2005-05-10 2006-05-10 ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 Pending JP2008540558A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67948005P 2005-05-10 2005-05-10
US72009905P 2005-09-23 2005-09-23
PCT/US2006/018182 WO2006122223A2 (en) 2005-05-10 2006-05-10 Strategies for delivery of active agents using micelles and particles

Publications (2)

Publication Number Publication Date
JP2008540558A true JP2008540558A (ja) 2008-11-20
JP2008540558A5 JP2008540558A5 (https=) 2009-07-02

Family

ID=37056867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511345A Pending JP2008540558A (ja) 2005-05-10 2006-05-10 ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略

Country Status (7)

Country Link
US (1) US20100062968A1 (https=)
EP (1) EP1893661B1 (https=)
JP (1) JP2008540558A (https=)
AT (1) ATE541875T1 (https=)
AU (1) AU2006243960A1 (https=)
CA (1) CA2608086A1 (https=)
WO (1) WO2006122223A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528154A (ja) * 2009-05-27 2012-11-12 セレクタ バイオサイエンシーズ インコーポレーテッド 免疫調節薬のｐＨ感応性放出がある標的指向性合成ナノキャリア
WO2014157150A1 (ja) * 2013-03-25 2014-10-02 日油株式会社 ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
KR20150136085A (ko) * 2013-03-11 2015-12-04 크리스탈 딜리버리 비.브이. 백신접종 조성물

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008062909A1 (en) * 2006-11-22 2008-05-29 The University Of Tokyo ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE
JP2010523656A (ja) * 2007-04-12 2010-07-15 エモリー・ユニバーシティ ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略
WO2009014476A1 (en) * 2007-07-24 2009-01-29 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
JP2012513448A (ja) * 2008-12-22 2012-06-14 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 自己免疫疾患および炎症性疾患の処置ための化合物および方法
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US20130058901A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Transplantable graft-specific induced tolerogenic dendritic cells and methods of use
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
US9919058B2 (en) 2014-07-15 2018-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
MX2018010586A (es) * 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
CN106750333B (zh) * 2016-12-06 2019-09-24 长春斯菲尔生物科技有限公司 一种改性的聚缩酮pcadk及制备方法和医用用途
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2020112913A1 (en) 2018-11-26 2020-06-04 Duke University Compositions and methods for inducing scarring by peri-tumoral cells
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CN115192524B (zh) * 2021-04-13 2023-08-29 杭州汉菁生物科技有限公司 一种包载链状难溶药物的聚合型胶束及制备方法和应用
WO2023086073A1 (en) * 2021-11-09 2023-05-19 Massachusetts Institute Of Technology Particles containing pollutant-capturing micelles and related methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
JPS619431A (ja) * 1984-06-06 1986-01-17 メルク　エンド　カムパニー　インコーポレーテツド ペンダント酸性官能基及び不安全な主鎖結合を有するポリマー
JPS63314239A (ja) * 1982-09-30 1988-12-22 アモコ・コーポレイシヨン ポリケタール重合体
WO2003059988A2 (en) * 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4950795A (en) * 1987-08-27 1990-08-21 Ciba-Geigy Corporation Oligomeric benzil ketals and their use as photoinitiators
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2007098041A1 (en) * 2006-02-17 2007-08-30 Medtronic, Inc. Polyketal polymers, and methods of making and using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
JPS63314239A (ja) * 1982-09-30 1988-12-22 アモコ・コーポレイシヨン ポリケタール重合体
JPS619431A (ja) * 1984-06-06 1986-01-17 メルク　エンド　カムパニー　インコーポレーテツド ペンダント酸性官能基及び不安全な主鎖結合を有するポリマー
WO2003059988A2 (en) * 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5008006572; ＳＴ．　ＰＩＥＲＲＥ，　ＴＨＯＭＡＳ　ｅｔ　ａｌ．: ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＡＣＴＩＶＥ　ＡＮＤ　ＣＯＭＰＡＴＩＢＬＥ　ＰＯＬＹＭＥＲＳ Ｖｏｌ．　２，　Ｎｏ．　１, 1987, ｐ．　４-３０ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528154A (ja) * 2009-05-27 2012-11-12 セレクタ バイオサイエンシーズ インコーポレーテッド 免疫調節薬のｐＨ感応性放出がある標的指向性合成ナノキャリア
US9006254B2 (en) 2009-05-27 2015-04-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
JP2016053048A (ja) * 2009-05-27 2016-04-14 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 免疫調節薬のｐＨ感応性放出がある標的指向性合成ナノキャリア
US9884112B2 (en) 2009-05-27 2018-02-06 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
JP2018065808A (ja) * 2009-05-27 2018-04-26 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 免疫調節薬のｐＨ感応性放出がある標的指向性合成ナノキャリア
KR20150136085A (ko) * 2013-03-11 2015-12-04 크리스탈 딜리버리 비.브이. 백신접종 조성물
KR102266567B1 (ko) 2013-03-11 2021-06-21 크리스탈 딜리버리 비.브이. 백신접종 조성물
WO2014157150A1 (ja) * 2013-03-25 2014-10-02 日油株式会社 ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
US10023693B2 (en) 2013-03-25 2018-07-17 Nof Corporation Hydrophilic polymer derivative having benzylidene acetal linker
US10633489B2 (en) 2013-03-25 2020-04-28 Nof Corporation Hydrophilic polymer derivative having benzylidene acetal linker

Also Published As

Publication number Publication date
WO2006122223A2 (en) 2006-11-16
CA2608086A1 (en) 2006-11-16
ATE541875T1 (de) 2012-02-15
WO2006122223A3 (en) 2007-05-18
AU2006243960A1 (en) 2006-11-16
EP1893661A2 (en) 2008-03-05
EP1893661B1 (en) 2012-01-18
US20100062968A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
EP1893661B1 (en) Strategies for delivery of active agents using micelles and particles
US8252846B2 (en) Strategies for delivery of active agents using micelles and particles
JP2010523656A (ja) ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略
JP7491869B2 (ja) ペプチドコンジュゲート粒子
KR102485789B1 (ko) 펩티드-접합된 입자
JP5506196B2 (ja) 免疫治療のためのナノ粒子
US20190209474A1 (en) Methods of treating inflammatory and autoimmune diseases and disorders
Heffernan et al. Disulfide-crosslinked polyion micelles for delivery of protein therapeutics
Song et al. Photoresponsive polypeptide-glycosylated dendron amphiphiles: UV-triggered polymersomes, OVA release, and in vitro enhanced uptake and immune response
Sinsinbar et al. Amphiphilic block copolymer nanostructures as a tunable delivery platform: perspective and framework for the future drug product development
JP2025508933A (ja) ポリオキサゾリンおよび／またはポリオキサジンポリマーを含むｒｎａ脂質ナノ粒子（ｌｎｐ）
Yuan et al. Modulating elasticity of liposome for enhanced cancer immunotherapy
Lamrayah et al. Molecular modelling of TLR agonist Pam3CSK4 entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality
Zhang et al. Dual-targeting polymer nanoparticles efficiently deliver DNA vaccine and induce robust prophylactic immunity against spring viremia of carp virus infection
Takano et al. Molecular bottlebrushes for immunostimulatory CpG ODN delivery: relationship among cation density, complex formation ability, and cytotoxicity
Tang et al. Condensate nanovaccine adjuvants augment CD8+ T-Cell-dependent antitumor immunity through mtDNA leakage-triggered cGAS-STING axis activation
Gupta et al. Tolerogenic Modulation of the Immune Response by Oligoglycerol–and Polyglycerol–Peptide Conjugates
Bridgeman et al. Synthetic organic materials for targeting immunotherapies to lymph nodes
WO2022098467A1 (en) Methods, compositions and vaccine for autoimmune diseases and allergy treatment
Jha et al. A Biologically Inert Tamoxifen-Derived Long-Lasting Hydrogel-Mediated Immunochemotherapy Can Mitigate Tumor Progression and Activate T Cell Immunity
Tsai Leveraging Biomaterials to Direct Immune Function in Cancer and Autoimmunity
US20230355801A1 (en) Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
EP4608373A1 (en) Nanoparticles, vaccine compositions, procedures, uses, and methods of administration thereof
Stiepel Kinetics of Drug Release from Acetalated Dextran Microparticles and Applications in Immune Engineering
Elhasade Evaluation of Nanoparticle Formulation for Novel Synthetic Immune Stimulating Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121022